Inhibitors of the anaplastic lymphoma kinase

Bibliography

• Iwahara T, Fujimoto J, Wen D, Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 1997;14:439-49
   PubMed Web of Science ®Google Scholar
• Morris SW, Kirstein MN, Valentine MB, Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994;263:1281-4
   PubMed Web of Science ®Google Scholar
• Gaidano G, Dalla-Favera R. editors. Pathobiology of non-Hodgkin lymphomas. Churchill Livingstone; New York, NY: 2000
   Google Scholar
• Chiarle R, Voena C, Ambrogio C, The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008;8:11-23
   PubMed Web of Science ®Google Scholar
• Colleoni GW, Bridge JA, Garicochea B, ATIC-ALK: a novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35). Am J Pathol 2000;156:781-9
   PubMed Web of Science ®Google Scholar
• Cools J, Wlodarska I, Somers R, Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 2002;34:354-62
   PubMed Web of Science ®Google Scholar
• Hernandez L, Pinyol M, Hernandez S, TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. Blood 1999;94:3265-8
   PubMed Web of Science ®Google Scholar
• Lamant L, Dastugue N, Pulford K, A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation. Blood 1999;93:3088-95
   PubMed Web of Science ®Google Scholar
• Lamant L, Gascoyne RD, Duplantier MM, Non-muscle myosin heavy chain (MYH9): a new partner fused to ALK in anaplastic large cell lymphoma. Genes Chromosomes Cancer 2003;37:427-32
   PubMed Web of Science ®Google Scholar
• Tort F, Pinyol M, Pulford K, Molecular characterization of a new ALK translocation involving moesin (MSN-ALK) in anaplastic large cell lymphoma. Lab Invest 2001;81:419-26
   PubMed Web of Science ®Google Scholar
• Touriol C, Greenland C, Lamant L, Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing alk kinase fused to CLTCL (clathrin chain polypeptide-like). Blood 2000;95:3204-7
   PubMed Web of Science ®Google Scholar
• Beltran B, Castillo J, Salas R, ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. J Hematol Oncol 2009;2:11
   PubMed Web of Science ®Google Scholar
• Takeuchi K, Soda M, Togashi Y, Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma. Haematologica 2011;96:464-7
   PubMed Web of Science ®Google Scholar
• Delsol G, Lamant L, Mariame B, A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation. Blood 1997;89:1483-90
   PubMed Web of Science ®Google Scholar
• Lawrence B, Perez-Atayde A, Hibbard MK, TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am J Pathol 2000;157:377-84
   PubMed Web of Science ®Google Scholar
• Panagopoulos I, Nilsson T, Domanski HA, Fusion of the SEC31L1 and ALK genes in an inflammatory myofibroblastic tumor. Int J Cancer 2006;118:1181-6
   PubMed Web of Science ®Google Scholar
• Bridge JA, Kanamori M, Ma Z, Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. Am J Pathol 2001;159:411-15
   PubMed Web of Science ®Google Scholar
• Debelenko LV, Arthur DC, Pack SD, Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor. Lab Invest 2003;83:1255-65
   PubMed Web of Science ®Google Scholar
• Ma Z, Hill DA, Collins MH, Fusion of ALK to the ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 2003;37:98-105
   PubMed Web of Science ®Google Scholar
• Gleason BC, Hornick JL. Inflammatory myofibroblastic tumours: where are we now? J Clin Pathol 2008;61:428-37
   PubMed Web of Science ®Google Scholar
• Takeuchi K, Soda M, Togashi Y, Pulmonary inflammatory myofibroblastic tumor expressing a novel fusion, PPFIBP1-ALK: reappraisal of anti-ALK immunohistochemistry as a tool for novel ALK fusion identification. Clin Cancer Res 2011;17:3341-8
   PubMed Web of Science ®Google Scholar
• Jazii FR, Najafi Z, Malekzadeh R, Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer. World J Gastroenterol 2006;12:7104-12
   PubMed Web of Science ®Google Scholar
• Du XL, Hu H, Lin DC, Proteomic profiling of proteins dysregulated in Chinese esophageal squamous cell carcinoma. J Mol Med (Berl) 2007;85:863-75
   PubMed Web of Science ®Google Scholar
• Marino-Enriquez A, Ou WB, Weldon CB, ALK rearrangement in sickle cell trait-associated renal medullary carcinoma. Genes Chromosomes Cancer 2011;50:146-53
   PubMed Web of Science ®Google Scholar
• Rottgers S, Gombert M, Teigler-Schlegel A, ALK fusion genes in children with atypical myeloproliferative leukemia. Leukemia 2010;24:1197-200
   PubMed Web of Science ®Google Scholar
• Soda M, Choi YL, Enomoto M, Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6
   PubMed Web of Science ®Google Scholar
• Togashi Y, Soda M, Sakata S, KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS One 2012;7:e31323
   PubMed Web of Science ®Google Scholar
• Rikova K, Guo A, Zeng Q, Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:1190-203
   PubMed Web of Science ®Google Scholar
• Takeuchi K, Choi YL, Togashi Y, KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009;15:3143-9
   PubMed Web of Science ®Google Scholar
• Lipson D, Capelletti M, Yelensky R, Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 2012;18:382-4
   PubMed Web of Science ®Google Scholar
• Takeuchi K, Soda M, Togashi Y, RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012;18:378-81
   PubMed Web of Science ®Google Scholar
• Lin E, Li L, Guan Y, Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res 2009;7:1466-76
   PubMed Web of Science ®Google Scholar
• Chen Y, Takita J, Choi YL, Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008;455:971-4
   PubMed Web of Science ®Google Scholar
• George RE, Sanda T, Hanna M, Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008;455:975-8
   PubMed Web of Science ®Google Scholar
• Janoueix-Lerosey I, Lequin D, Brugieres L, Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008;455:967-70
   PubMed Web of Science ®Google Scholar
• Mosse YP, Laudenslager M, Longo L, Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008;455:930-5
   PubMed Web of Science ®Google Scholar
• Murugan AK, Xing M. Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene. Cancer Res 2011;71:4403-11
   PubMed Web of Science ®Google Scholar
• Wood LD, Parsons DW, Jones S, The genomic landscapes of human breast and colorectal cancers. Science 2007;318:1108-13
   PubMed Web of Science ®Google Scholar
• Ding L, Getz G, Wheeler DA, Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008;455:1069-75
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15
   PubMed Web of Science ®Google Scholar
• Wei X, Walia V, Lin JC, Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet 2011;43:442-6
   PubMed Web of Science ®Google Scholar
• Osajima-Hakomori Y, Miyake I, Ohira M, Biological role of anaplastic lymphoma kinase in neuroblastoma. Am J Pathol 2005;167:213-22
   PubMed Web of Science ®Google Scholar
• Salido M, Pijuan L, Martinez-Aviles L, Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer. J Thorac Oncol 2011;6:21-7
   PubMed Web of Science ®Google Scholar
• Stachurski D, Miron PM, Al-Homsi S, Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma with a complex karyotype and Cryptic 3' ALK gene insertion to chromosome 4 q22-24. Hum Pathol 2007;38:940-5
   PubMed Web of Science ®Google Scholar
• Hudson L, Kulig K, Young D, ALK and cMET expression in Glioblastoma multiforme: implications for therapeutic targeting. Mol Cancer Ther 2011;10:abstract #A42
   Google Scholar
• Grzelinski M, Steinberg F, Martens T, Enhanced antitumorigenic effects in Glioblastoma on double targeting of pleiotrophin and its receptor ALK. Neoplasia 2009;11:145-56
   PubMed Web of Science ®Google Scholar
• Powers C, Aigner A, Stoica GE, Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth. J Biol Chem 2002;277:14153-8
   PubMed Web of Science ®Google Scholar
• Cosmic catalogue of somatic mutations in cancer. Available from: http://www.sanger.ac.uk/genetics/cgp/cosmic/
   Google Scholar
• I.A.R.C. Globocan 2008
   Google Scholar
• Bekkenk MW, Geelen FA, Van Voorst Vader PC, Primary and secondary cutaneous CD30(+) Lymphoproliferative disorders: a report from the Dutch cutaneous lymphoma group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000;95:3653-61
   PubMed Web of Science ®Google Scholar
• Fanin R, Sperotto A, Silvestri F, The therapy of primary adult systemic CD30-positive anaplastic large cell lymphoma: results of 40 cases treated in a single center. Leuk Lymphoma 1999;35:159-69
   PubMed Web of Science ®Google Scholar
• Deconinck E, Lamy T, Foussard C, Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trial. Br J Haematol 2000;109:736-42
   PubMed Web of Science ®Google Scholar
• Younes A. CD30-targeted antibody therapy. Curr Opin Oncol 2011;23:587-93
   PubMed Web of Science ®Google Scholar
• Younes A, Yasothan U, Kirkpatrick P. Brentuximab vedotin. Nat Rev Drug Discov 2012;11:19-20
   PubMed Web of Science ®Google Scholar
• Reck M. Current approaches in chemotherapy of advanced and metastatic non-small cell lung cancer (NSCLC). Anticancer Res 2005;25:1501-6
   PubMed Web of Science ®Google Scholar
• Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 2010;10:760-74
   PubMed Web of Science ®Google Scholar
• Cui JJ, Tran-Dube M, Shen H, Structure based drug design of Crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem 2011;54:6342-63
   PubMed Web of Science ®Google Scholar
• Zou HY, Li Q, Lee JH, An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007;67:4408-17
   PubMed Web of Science ®Google Scholar
• Christensen JG, Zou HY, Arango ME, Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007;6:3314-22
   PubMed Web of Science ®Google Scholar
• Kwak EL, Camidge DR, Clark J, Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. J Clin Oncol 2009;27:3509
   Web of Science ®Google Scholar
• Kwak EL, Bang YJ, Camidge DR, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703
   PubMed Web of Science ®Google Scholar
• Li C, Alvey C, Bello A, Pharmacokinetics (PK) of Crizotinib (PF-02341066) in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors. J Clin Oncol 2011;29:e13065
   Web of Science ®Google Scholar
• Butrynski JE, D'adamo DR, Hornick JL, Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med 2010;363:1727-33
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Messa C, Pogliani EM. Crizotinib in anaplastic large-cell lymphoma. N Engl J Med 2011;364:775-6
   PubMed Web of Science ®Google Scholar
• Shaw AT, Yeap BY, Solomon BJ, Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011;12:1004-12
   PubMed Web of Science ®Google Scholar
• Crino L, Kim D, Riely GJ, Initial phase II results with Crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): profile 1005. J Clin Oncol 2011;29:7514
   Web of Science ®Google Scholar
• Choi YL, Soda M, Yamashita Y, EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010;363:1734-9
   PubMed Web of Science ®Google Scholar
• Doebele RC, Pilling AB, Aisner D, Mechanisms of resistance to Crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012;18:1472-82
   PubMed Web of Science ®Google Scholar
• Sasaki T, Koivunen J, Ogino A, A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 2011;71:6051-60
   PubMed Web of Science ®Google Scholar
• Sasaki T, Okuda K, Zheng W, The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res 2010;70:10038-43
   PubMed Web of Science ®Google Scholar
• Gorre ME, Mohammed M, Ellwood K, Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Boggon TJ, Dayaram T, EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92
   PubMed Web of Science ®Google Scholar
• Bresler SC, Wood AC, Haglund EA, Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Sci Transl Med 2011;3:108ra14
   Web of Science ®Google Scholar
• Katayama R, Shaw AT, Khan TM, Mechanisms of acquired Crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 2012;4:120ra17
   PubMed Web of Science ®Google Scholar
• Katayama R, Khan TM, Benes C, Therapeutic strategies to overcome Crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci USA 2011;108:7535-40
   PubMed Web of Science ®Google Scholar
• Rivera VM, Anjum R, Wang F, Efficacy and pharmacodynamic analysis of AP26113, a potent and selective orally active inhibitor of anaplastic lymphoma kinase (ALK). AACR 2010; 2010. Poster #3623
   Google Scholar
• Sakamoto H, Tsukaguchi T, Hiroshima S, CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 2011;19:679-90
   PubMed Web of Science ®Google Scholar
• Galkin AV, Melnick JS, Kim S, Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci USA 2007;104:270-5
   PubMed Web of Science ®Google Scholar
• Li N, Michellys PY, Kim S, Activity of a potent and selective phase I ALK inhibitor LDK378 in naive and Crizotinib-resistant preclinical tumor models. Mol Cancer Ther 2011;10:abstract B232
   Google Scholar
• El-Deeb IM, Yoo KH, Lee SH. ROS receptor Tyrosine Kinase: a new potential target for anticancer drugs. Med Res Rev 2011;31:794-818
   PubMed Web of Science ®Google Scholar
• Kuromitsu S, Mori M, Shimada I, Anti-tumor activity of ASP3026, A novel and selective ALK inhibitor [abstract #2821]. Proceedings of the 102nd annual meeting of the American association for cancer research 2011
   Google Scholar
• Gambacorti-Passerini C, Antolini L, Mahon FX, Multicenter independent assessment of outcomes in chronic myeloid Leukemia patients treated with Imatinib. J Natl Cancer Inst 103:553-61
   PubMed Web of Science ®Google Scholar
• Benson ES. Leukemia and the Philadelphia chromosome. Postgrad Med 1961;30:A22-A8
   PubMed Web of Science ®Google Scholar
• Zuccotto F, Ardini E, Casale E, Through the "Gatekeeper Door": exploiting the active kinase conformation. J Med Chem 2010;53:2681-94
   PubMed Web of Science ®Google Scholar